European Price Controls Will Erode Immunotherapy Viability

Key Takeaways

• Reliance on favorable drug pricing and a single lead product increases vulnerability to future regulatory and market shifts, risking income and growth stability.
  
• Escalating competition and regulatory hurdles threaten both technology relevance and clinical pipeline progress, undermining long-term commercial viability.
  
• Sustained demand for core product, expanding global reach, diverse clinical pipeline, solid pricing power, and strong financial position support robust growth and reduced risk.

Catalysts

A commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases.

• Mounting global political scrutiny on drug pricing could lead to stricter pricing controls and reimbursement challenges, especially in Europe where Immunocore's revenue growth has recently relied on favorable price negotiations and ongoing launches, significantly increasing the risk of future revenue and margin compression.
  
• Accelerating healthcare cost containment and value-based reimbursement trends threaten Immunocore's ability to secure premium pricing and broad payer coverage for both existing and pipeline assets, placing downward pressure on long-term net margins if cost-effectiveness criteria are not met.
  
• Heavy dependence on KIMMTRAK exposes Immunocore to severe revenue volatility, as any failure in Phase III trials, competitive displacement, or changes in treatment practice could cause an abrupt decline in revenue and stall growth given the lack of near-term alternative commercialized products.
  
• Intensifying competition from emerging and established immunotherapy modalities, such as CAR-T, CRISPR, and bispecific antibodies, poses a long-term existential threat to TCR-based therapies, raising the risk that Immunocore's core technology becomes less commercially viable and eroding potential future earnings and market share.
  
• Regulatory uncertainty and evolving approval standards for novel immunotherapies may lead to lengthy, costly, or unsuccessful clinical development, with potential delays in TEBE-AM, ATOM, and PRISM-MEL Phase III readouts, thus exhausting cash reserves and preventing Immunocore from achieving profitability or sustained positive earnings.

Immunocore Holdings Future Earnings and Revenue Growth

Assumptions

• This narrative explores a more pessimistic perspective on Immunocore Holdings compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• The bearish analysts are assuming Immunocore Holdings's revenue will grow by 3.7% annually over the next 3 years.
• The bearish analysts are not forecasting that Immunocore Holdings will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Immunocore Holdings's profit margin will increase from -5.7% to the average US Biotechs industry of 16.3% in 3 years.
• If Immunocore Holdings's profit margin were to converge on the industry average, you could expect earnings to reach $64.6 million (and earnings per share of $1.27) by about August 2028, up from $-20.3 million today. The analysts are largely in agreement about this estimate.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 24.4x on those 2028 earnings, up from -81.6x today. This future PE is greater than the current PE for the US Biotechs industry at 15.6x.
• Analysts expect the number of shares outstanding to grow by 0.74% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.47%, as per the Simply Wall St company report.

Immunocore Holdings Future Earnings Per Share Growth

Risks

• Strong and consistent revenue growth from KIMMTRAK, with 32% year-over-year increase and 13 consecutive quarters of sales growth, suggests sustained high demand and supports the potential for continued revenue and earnings expansion.
  
• Expansion of the addressable market through new country launches (now in 28 countries and approved in 39), growing penetration in both the U.S. and Europe, and further global partnerships (such as the Er-Kim collaboration for Turkey and MENA) enable incremental revenue streams and long-term top line growth.
  
• Robust clinical pipeline with three ongoing Phase III trials and multiple early-stage assets in oncology, infectious disease, and autoimmunity, provides significant opportunities for future product diversification, de-risks dependence on a single product, and can drive future revenue growth.
  
• Demonstrated ability to negotiate favorable pricing outcomes and achieve strong market access in Europe, alongside high prescription rates and durable therapy duration (13 months), indicate a strong value proposition and can help maintain healthy gross margins over time.
  
• The company maintains a strong balance sheet with $883 million in cash and marketable securities, allowing for continued investment in R&D and commercialization initiatives without near-term dilutive funding, which can support stable or growing net margins and shareholder value.

Valuation

• The assumed bearish price target for Immunocore Holdings is $24.92, which represents the lowest price target estimate amongst analysts. This valuation is based on what can be assumed as the expectations of Immunocore Holdings's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $100.0, and the most bearish reporting a price target of just $24.92.
• In order for you to agree with the bearish analysts, you'd need to believe that by 2028, revenues will be $397.5 million, earnings will come to $64.6 million, and it would be trading on a PE ratio of 24.4x, assuming you use a discount rate of 7.5%.
• Given the current share price of $32.88, the bearish analyst price target of $24.92 is 31.9% lower. Despite analysts expecting the underlying buisness to improve, they seem to believe the market's expectations are too high.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.